The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic in...
Guardado en:
Autores principales: | Juan P. Palavicini, Alberto Chavez-Velazquez, Marcel Fourcaudot, Devjit Tripathy, Meixia Pan, Luke Norton, Ralph A. DeFronzo, Christopher E. Shannon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/335d5896954c4b0ea9323a843dc2c1dd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz S
Publicado: (2010) -
Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
por: M. V. Shestakova, et al.
Publicado: (2021) -
Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats
por: Szu-Yu Liu, et al.
Publicado: (2021) -
Stabilization by Nano Spray Dryer of Pioglitazone Polymeric Nanosystems: Development, In Vivo, Ex Vivo and Synchrotron Analysis
por: Marcelle Silva-Abreu, et al.
Publicado: (2021) -
A Lipidomics Atlas of Selected Sphingolipids in Multiple Mouse Nervous System Regions
por: Chunyan Wang, et al.
Publicado: (2021)